Press Releases Corvus Pharmaceuticals, Inc.

Equities

CRVS

US2210151005

Real-time Estimate Cboe BZX Other stock markets 14:49:58 2024-05-09 EDT			5-day change	1st Jan Change
2.085 ^USD	+6.38%		+20.58%	+18.52%

05-07	Corvus Pharmaceuticals Insider Bought Shares Worth $1,000,000, According to a Recent SEC Filing	MT
05-07	Oppenheimer Adjusts Price Target on Corvus Pharmaceuticals to $8 From $7, Maintains Outperform Rating	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Corvus: Q1 Earnings Snapshot	05-06	AQ
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results	05-06	AQ
Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024	05-02	AQ
Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering	05-02	AQ
Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis	04-09	AQ
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	03-20	AQ
Corvus: Q4 Earnings Snapshot	03-19	AQ
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	03-19	AQ
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024	03-13	AQ
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases	02-12	AQ
Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma	02-08	AQ
Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer	02-06	AQ
Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell	01-23	AQ
Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T cell Lymphoma Trial	12-11	AQ
Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial	12-09	AQ
Corvus: Q3 Earnings Snapshot	11-07	AQ
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results	11-07	AQ
Corvus Pharmaceuticals to Present New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition	11-02	AQ
Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases	11-01	AQ
Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter Financial Results on November 7, 2023	23-10-31	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Corvus Pharmaceuticals, Inc.

Equities

CRVS

US2210151005

Press Releases

Filters